Get the Stockscreener App
28.93
0.99%
-0.29
After Hours:
28.98
0.05
+0.17%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $28.93, with a volume of 22.46M.
It is down -0.99% in the last 24 hours and down -1.67% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$29.22
Open:
$29.22
24h Volume:
22.46M
Relative Volume:
0.76
Market Cap:
$163.94B
Revenue:
$55.64B
Net Income/Loss:
$-2.60B
P/E Ratio:
15.81
EPS:
1.83
Net Cash Flow:
$4.81B
1W Performance:
-0.52%
1M Performance:
-1.67%
6M Performance:
+11.27%
1Y Performance:
-5.61%
1-Day Range:
$28.88
$29.22
1-Week Range:
$28.88
$29.82
52-Week Range:
$25.20
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Pfizer (NYSE:PFE) Trading Down 0.7%Here's What Happened - MarketBeat
Pfizer’s RSVpreF Vaccine Shows Efficacy in High-Risk Adults Aged 18-59 - Contagionlive.com
Three AI Stocks To Buy That Aren't Nvidia - Benzinga
Erythromycin Market is Booming Worldwide with Players : Pfizer Inc , Abbott Laboratories - openPR
Pfizer Inc. (PFE): Among the Worst Performing Blue Chip Stocks in 2024 - Insider Monkey
Here's Why Pfizer (NYSE:PFE) Has A Meaningful Debt Burden - Yahoo Finance
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip? - The Motley Fool
Penn Davis Mcfarland Inc. Takes Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Non Muscle Invasive Bladder Cancer Market Breaking New Ground | Merck & Co., Inc., Ferring Pharmaceuticals, - EIN News
Pfizer: Activists Clouding A Promising Picture (NYSE:PFE) - Seeking Alpha
With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners - Simply Wall St
Creative Planning Has $52.69 Million Holdings in Pfizer Inc. (NYSE:PFE) - MarketBeat
Pfizer Inc. (NYSE:PFE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Goldman Sachs: Pfizer Inc. (NYSE:PFE) Is A Stock With High Consensus ROE - Yahoo Finance
KMG Fiduciary Partners LLC Makes New $2.89 Million Investment in Pfizer Inc. (NYSE:PFE) - MarketBeat
He Made Pfizer a Household Name. Wall Street Wants More. - The Wall Street Journal
Pfizer Inc. stock underperforms Friday when compared to competitors - MarketWatch
Pfizer (NYSE:PFE) Stock Price Down 0.4%What's Next? - MarketBeat
Pfizer Escapes 401(k) Fee Suit Due To Poor Comparisons - Law360
Pfizer 401(k) Plan Fee Lawsuit Dismissed for Faulty Comparisons - Bloomberg Law
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock - MSN
Sumitomo Mitsui DS Asset Management Company Ltd Boosts Position in Pfizer Inc. (NYSE:PFE) - MarketBeat
Is Pfizer Inc. (PFE) A Good Stock to Buy Right Now? - Yahoo Finance
Muscle Invasive Bladder Cancer Therapeutics Market Trends, Opportunites By 2032 | Pfizer Inc, Merck & Co, - EIN News
Preventive Healthcare Technologies And Services Market Projected To Witness Substantial Growth, 2024-2031: - EIN News
McPherson’s Pfizer plant lays off 80 people - AOL
Pfizer (NYSE:PFE) Trading Down 1.1%Here's Why - MarketBeat
Adrenal crisis Market on Track for Major Expansion by 2034, According to DelveInsight | Takeda Pharma, Sandoz International GmbH, Pfizer Inc, Bristol-Myers Squibb, Merck KGaA, Antares Pharma - The Globe and Mail
Bernstein Initiates Coverage of Pfizer (PFE) with Market Perform Recommendation - Nasdaq
Is Pfizer Stock A Sell As It Wages Battle With An Activist Investor? - Investor's Business Daily
The Escalator: Pfizer, David Cameron, Elizabeth Warren and more - MM+M Online
Over The Counter Pain Medication Market Projected To Witness Substantial Growth 2024-2031:Pfizer Inc.,Bayer - EIN News
Success for Pfizer and Marks & Clerk as UK High Court revokes GSK patents - JUVE Patent
IQ EQ FUND MANAGEMENT IRELAND Ltd Acquires 23,928 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
Cabinet Chairman Japarov discusses cooperation with Apple, Pfizer - AKIpress
Pfizer's Ibrance shows promise in treating appendix cancer: study (NYSE:PFE) - Seeking Alpha
Pfizer (NYSE:PFE) Trading Up 0.6%Should You Buy? - MarketBeat
Why I'm Considering Leaning Heavily Into Pfizer - sharewise
Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle - Benzinga
IsomAb announces Development Candidate nomination with Pfizer for Peripheral Arterial Disease - The Financial Express
Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.
Foster Victor Wealth Advisors LLC Purchases 18,162 Shares of Pfizer Inc. (NYSE:PFE) - MarketBeat
An Van Gerven Is Appointed President of Pfizer Canada - BioSpace
Pfizer sticks $1.5bn on Triana's molecular glue tech - pharmaphorum
Pfizer Independent Medical Education RFPs: Competitive Grant Program - fundsforNGOs
Guggenheim caught in Starboard-Pfizer crossfire - Financial Times
What to Expect From Pfizer's Q3 2024 Earnings Report - Nasdaq
Pfizer, Triana Launch Up-to-$1.5B+ Molecular Glue Collaboration - Genetic Engineering & Biotechnology News
Starboard-Pfizer battle strains Guggenheim’s relationship with drugmaker - Financial Times
Pfizer (NYSE:PFE) Trading Up 1.9%What's Next? - MarketBeat
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):